A detailed history of Vanguard Group Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Vanguard Group Inc holds 3,345,731 shares of VRDN stock, worth $73.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,345,731
Previous 3,234,279 3.45%
Holding current value
$73.8 Million
Previous $56.6 Million 23.14%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$11.6 - $17.26 $1.29 Million - $1.92 Million
111,452 Added 3.45%
3,345,731 $43.5 Million
Q1 2024

May 10, 2024

BUY
$17.09 - $23.82 $3.99 Million - $5.56 Million
233,331 Added 7.78%
3,234,279 $56.6 Million
Q4 2023

Feb 14, 2024

BUY
$11.12 - $22.5 $6.15 Million - $12.4 Million
552,933 Added 22.59%
3,000,948 $65.4 Million
Q3 2023

Nov 14, 2023

SELL
$15.16 - $24.7 $2.25 Million - $3.67 Million
-148,629 Reduced 5.72%
2,448,015 $37.6 Million
Q2 2023

Aug 14, 2023

BUY
$22.57 - $29.67 $10.5 Million - $13.8 Million
466,411 Added 21.89%
2,596,644 $61.8 Million
Q1 2023

May 15, 2023

BUY
$25.04 - $37.6 $381,584 - $572,986
15,239 Added 0.72%
2,130,233 $54.2 Million
Q4 2022

Feb 10, 2023

BUY
$18.78 - $29.74 $4.85 Million - $7.68 Million
258,194 Added 13.91%
2,114,994 $61.8 Million
Q3 2022

Nov 14, 2022

BUY
$10.7 - $25.5 $4.77 Million - $11.4 Million
445,898 Added 31.6%
1,856,800 $38.1 Million
Q2 2022

Aug 12, 2022

BUY
$9.55 - $19.0 $4.49 Million - $8.94 Million
470,325 Added 50.0%
1,410,902 $16.3 Million
Q1 2022

May 13, 2022

BUY
$16.79 - $20.88 $250,187 - $311,132
14,901 Added 1.61%
940,577 $17.4 Million
Q4 2021

Feb 14, 2022

BUY
$15.65 - $21.5 $7.26 Million - $9.97 Million
463,764 Added 100.4%
925,676 $18.3 Million
Q3 2021

Nov 12, 2021

BUY
$10.69 - $18.2 $1.15 Million - $1.96 Million
107,846 Added 30.46%
461,912 $7.6 Million
Q2 2021

Aug 13, 2021

BUY
$14.34 - $18.67 $5.08 Million - $6.61 Million
354,066 New
354,066 $6.48 Million

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $880M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.